Cost of Managing Type 2 Diabetes Before and After Initiating Dipeptidyl Peptidase 4 Inhibitor Treatment: A Longitudinal Study Using a French Public Health Insurance Database

Overview

Journal Diabetes Ther

Specialty Cardiology & Vascular Diseases

Date 2020 Jan 19

PMID 31953694

Citations 1

Authors

Corinne Emery

Elodie Torreton

Sylvie Dejager

Laurie Levy-Bachelot

Sebastien Bineau

Bruno Detournay

Affiliations

Soon will be listed here.

Abstract

Introduction: Diabetes is a growing epidemic that imposes a substantial economic burden on healthcare systems. This study aimed to evaluate the cost of managing type 2 diabetes (T2D) with dipeptidyl peptidase 4 inhibitors (DPP4Is) using real-world data.

Method: This longitudinal study used data from the French EGB (Echantillon Généraliste des Bénéficiaires) database. The annual average direct healthcare cost of treating patients with T2D was calculated 3 years prior and 3 years after initiation of DPP4I therapy. Actual total ambulatory and hospital care expenditure for the 3 years after DPP4I initiation was compared to projected costs. The distribution of costs across all care modalities was assessed over the 6-year period.

Results: Ambulatory and hospital care expenditure data for 919 patients with T2D starting DPP4I therapy alone or in combination in 2013 were analyzed. A total of 526 patients (57.2%) were still being treated with DPP4I 3 years after DPP4I initiation. Regardless of the treatment regimen, the ambulatory and hospital care costs increased above projected costs in the first year following DPP4I initiation, and then declined during the second and third years to levels in line with or below projected values for patients using DPP4Is as an add-on therapy. The increase in total expenditure in the first year following DPP4I initiation and the subsequent decline in costs in the second and third years were both associated with general trends in consumption across all aspects of patient care.

Conclusion: Despite an initial increase in healthcare expenditure, concomitant with reevaluation of patient care, this study showed that initiation of DPP4Is as an add-on therapy in French patients with T2D was associated with care expenditure that was in line or below predicted values within the 3 years following treatment initiation. Additional studies are required to evaluate the economic impact of the long-term treatment benefits.

Citing Articles

Sex, age, type of diabetes and incidence of atrial fibrillation in patients with diabetes mellitus: a nationwide analysis.

Bisson A, Bodin A, Fauchier G, Herbert J, Angoulvant D, Ducluzeau P Cardiovasc Diabetol. 2021; 20(1):24.

PMID: 33482830 PMC: 7821402. DOI: 10.1186/s12933-021-01216-7.

References

Gallwitz B . Management of patients with type 2 diabetes and mild/moderate renal impairment: profile of linagliptin. Ther Clin Risk Manag. 2015; 11:799-805. PMC: 4437596. DOI: 10.2147/TCRM.S67076. View

Laiteerapong N, Ham S, Gao Y, Moffet H, Liu J, Huang E . The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2018; 42(3):416-426. PMC: 6385699. DOI: 10.2337/dc17-1144. View

Karagiannis T, Paschos P, Paletas K, Matthews D, Tsapas A . Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012; 344:e1369. DOI: 10.1136/bmj.e1369. View

Valensi P, de Pouvourville G, Benard N, Chanut-Vogel C, Kempf C, Eymard E . Treatment maintenance duration of dual therapy with metformin and sitagliptin in type 2 diabetes: The ODYSSEE observational study. Diabetes Metab. 2015; 41(3):231-8. DOI: 10.1016/j.diabet.2015.03.007. View

Khunti K, Seidu S . Therapeutic Inertia and the Legacy of Dysglycemia on the Microvascular and Macrovascular Complications of Diabetes. Diabetes Care. 2019; 42(3):349-351. DOI: 10.2337/dci18-0030. View

Scheen A . DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials. Diabetes Metab. 2011; 38(2):89-101. DOI: 10.1016/j.diabet.2011.11.001. View

Brodovicz K, Chen Y, Liu Z, Ritchey M, Liao J, Engel S . Characterization of Sitagliptin Use in Patients with Type 2 Diabetes and Chronic Kidney Disease by Cross-Sectional Analysis of a Medical Insurance Claims Database. Diabetes Ther. 2015; 6(4):627-634. PMC: 4674473. DOI: 10.1007/s13300-015-0133-z. View

Hanaire H, Attali C, Lecointre B, Fraysse M, Gouet D, Babel M . [Determinants of the cost of initiation of insulin therapy type 2 diabetic patients in France: possible approaches to optimization]. Sante Publique. 2017; 28(6):781-789. View

de Lagasnerie G, Aguade A, Denis P, Fagot-Campagna A, Gastaldi-Menager C . The economic burden of diabetes to French national health insurance: a new cost-of-illness method based on a combined medicalized and incremental approach. Eur J Health Econ. 2017; 19(2):189-201. PMC: 5813074. DOI: 10.1007/s10198-017-0873-y. View

10.

Amori R, Lau J, Pittas A . Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007; 298(2):194-206. DOI: 10.1001/jama.298.2.194. View

11.

Baptista A, Teixeira I, Romano S, Vaz Carneiro A, Perelman J . The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies. Eur J Health Econ. 2016; 18(8):937-965. DOI: 10.1007/s10198-016-0837-7. View

12.

Bowrin K, Briere J, Levy P, Millier A, Clay E, Toumi M . Cost-effectiveness analyses using real-world data: an overview of the literature. J Med Econ. 2019; 22(6):545-553. DOI: 10.1080/13696998.2019.1588737. View

13.

Cai B, Katz L, Alexander C, Williams-Herman D, Girman C . Characteristics of patients prescribed sitagliptin and other oral antihyperglycaemic agents in a large US claims database. Int J Clin Pract. 2010; 64(12):1601-8. DOI: 10.1111/j.1742-1241.2010.02516.x. View

14.

Charbonnel B, Simon D, Dallongeville J, Bureau I, Dejager S, Levy-Bachelot L . Direct Medical Costs of Type 2 Diabetes in France: An Insurance Claims Database Analysis. Pharmacoecon Open. 2018; 2(2):209-219. PMC: 5972121. DOI: 10.1007/s41669-017-0050-3. View

15.

Zhang Q, Rajagopalan S, Mavros P, Engel S, Davies M, Yin D . Baseline characteristic differences between patients prescribed sitagliptin vs. other oral antihyperglycemic agents: analysis of a US electronic medical record database. Curr Med Res Opin. 2010; 26(7):1697-703. DOI: 10.1185/03007995.2010.489029. View

16.

Bernal J, Cummins S, Gasparrini A . The use of controls in interrupted time series studies of public health interventions. Int J Epidemiol. 2018; 47(6):2082-2093. DOI: 10.1093/ije/dyy135. View

17.

Geng J, Yu H, Mao Y, Zhang P, Chen Y . Cost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes. Pharmacoeconomics. 2015; 33(6):581-97. DOI: 10.1007/s40273-015-0266-y. View

18.

Wang T, McNeill A, Chen Y, ONeill E, Engel S . Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database. Diabetes Ther. 2018; 9(1):309-315. PMC: 5801246. DOI: 10.1007/s13300-017-0360-6. View

19.

Inzucchi S, Bergenstal R, Buse J, Diamant M, Ferrannini E, Nauck M . Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015; 58(3):429-42. DOI: 10.1007/s00125-014-3460-0. View

20.

Sullivan S, Mauskopf J, Augustovski F, Caro J, Lee K, Minchin M . Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health. 2014; 17(1):5-14. DOI: 10.1016/j.jval.2013.08.2291. View